Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Pfizer Inc. today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus ...

We rode over 350 miles over two days and utilized Rally Comp navigation system to follow the course of the 2025 Rugged Radios ...

Bithell returns to the world of Tron, but in a more action-acked fashion in the isometric adventure of Tron: Catalyst.

While the emergence of immune checkpoint inhibitors has improved cancer ... of neoadjuvant pembrolizumab administered after one cycle of neo-adjuvant chemotherapy in patients with untreated ...

However, resistance to CDK inhibitors frequently arises due to activation of compensatory pathways, such as the MEK-ERK signaling cascade, which drives unchecked cell cycle progression and circumvents ...

Cell-free DNA fragmentome dynamics as a biomarker for immune-checkpoint inhibition in advanced carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025 ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.